[go: up one dir, main page]

PE20080345A1 - Derivados de piperazina como agonistas del receptor de gpr38 - Google Patents

Derivados de piperazina como agonistas del receptor de gpr38

Info

Publication number
PE20080345A1
PE20080345A1 PE2007000819A PE2007000819A PE20080345A1 PE 20080345 A1 PE20080345 A1 PE 20080345A1 PE 2007000819 A PE2007000819 A PE 2007000819A PE 2007000819 A PE2007000819 A PE 2007000819A PE 20080345 A1 PE20080345 A1 PE 20080345A1
Authority
PE
Peru
Prior art keywords
methyl
phenyl
alkyl
piperazinyl
agonists
Prior art date
Application number
PE2007000819A
Other languages
English (en)
Inventor
Darren Jason Mitchell
Jonathan Thomas Seal
Mervyn Thompson
Susan Marie Westaway
Samantha Louisa Brown
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0612844A external-priority patent/GB0612844D0/en
Priority claimed from GB0711525A external-priority patent/GB0711525D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080345A1 publication Critical patent/PE20080345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I; DONDE A ES FENILO O UN ANILLO HETEROARILO DE 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4; B ES FENILO OPCIONALMENTE SUSTITUIDO, UN ANILLO HETEROARILO DE 6 MIEMBROS QUE PUEDE CONECTARSE AL CARBONO DE LA AMIDA; Y ES NH, N-ALQUILO C1-C4, O, C=O, CH2; R1 Y R2 SON CADA UNO H, ALQUILO C1-C4; R3 ES FENILO SUSTITUIDO O NO, HETEROARILO, HETEROCICLICO; R4 ES H, ALQUILO C1-C4, ALCOXIALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 6-(3-FLUOROFENIL)-N-METIL-N-(4-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}FENIL)-3-PIRIDINACARBOXAMIDA, 4'-FLUORO-N-METIL-N-(4-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}FENIL)-4-BIFENILCARBOXAMIDA, N-{4-{[(3R,5S)-3,5-DIMETIL-1-PIPERAZINIL]METIL} FENIL}-6-(4-FLUOROFENIL)-N,2-DIMETIL-3-PIRIDINACARBOXAMIDA, ENTRE OTROS. REFERIDA TAMBIEN A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON AGONISTAS DE GPR38 UTILES EN EL TRATAMIENTO DE REFLUJO GASTROESOFAGICO, DISPEPSIA FUNCIONAL, ESTRENIMIENTO, ILEO PARALITICO, ENTRE OTROS
PE2007000819A 2006-06-28 2007-06-26 Derivados de piperazina como agonistas del receptor de gpr38 PE20080345A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0612844A GB0612844D0 (en) 2006-06-28 2006-06-28 Compounds
GB0711525A GB0711525D0 (en) 2007-06-14 2007-06-14 Compounds

Publications (1)

Publication Number Publication Date
PE20080345A1 true PE20080345A1 (es) 2008-05-29

Family

ID=38476358

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000819A PE20080345A1 (es) 2006-06-28 2007-06-26 Derivados de piperazina como agonistas del receptor de gpr38

Country Status (29)

Country Link
US (2) US7700599B2 (es)
EP (1) EP2041093B1 (es)
JP (1) JP5028484B2 (es)
KR (1) KR20090031688A (es)
AR (1) AR061656A1 (es)
AT (1) ATE465150T1 (es)
AU (1) AU2007263712B2 (es)
BR (1) BRPI0713443A2 (es)
CA (1) CA2655540A1 (es)
CR (1) CR10497A (es)
CY (1) CY1110190T1 (es)
DE (1) DE602007006019D1 (es)
DK (1) DK2041093T3 (es)
EA (1) EA015820B1 (es)
ES (1) ES2344484T3 (es)
HR (1) HRP20100284T1 (es)
IL (1) IL195900A0 (es)
JO (1) JO2645B1 (es)
MA (1) MA30539B1 (es)
MX (1) MX2009000110A (es)
MY (1) MY147677A (es)
NO (1) NO20090266L (es)
NZ (1) NZ573450A (es)
PE (1) PE20080345A1 (es)
PL (1) PL2041093T3 (es)
PT (1) PT2041093E (es)
SI (1) SI2041093T1 (es)
TW (1) TWI391386B (es)
WO (1) WO2008000729A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
TWI376375B (en) 2005-07-26 2012-11-11 Glaxo Group Ltd Compounds
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
MX2009000110A (es) * 2006-06-28 2009-01-23 Glaxo Group Ltd Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38.
GB0723317D0 (en) * 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
WO2010098145A1 (en) 2009-02-27 2010-09-02 Raqualia Pharma Inc. Oxyindole derivatives with motilin receptor agonistic activity
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
SG188415A1 (en) * 2010-09-27 2013-04-30 Daiichi Sankyo Co Ltd Cyclohexane derivative compound
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
MA43706B1 (fr) 2016-03-17 2020-09-30 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar
IL301556A (en) * 2020-09-25 2023-05-01 Shanghai Meiyue Biotech Dev Co Ltd Pyrimidine carboxamide compound and its use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
JPH06211886A (ja) 1992-11-04 1994-08-02 Chugai Pharmaceut Co Ltd エリスロマイシン誘導体
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) * 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19644195A1 (de) 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6100239A (en) * 1996-11-26 2000-08-08 Chugai Seiyaku Kabushiki Kaisha 13-membered ring macrolide compound, medicine containing the same, and process for producing the same
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
PT1169038E (pt) * 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
US20020010184A1 (en) * 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020052380A1 (en) * 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
WO2001068621A1 (en) * 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
WO2001068622A1 (en) * 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
AU2001249144A1 (en) * 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclopentene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262195B2 (en) 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
CN101068773A (zh) * 2003-10-01 2007-11-07 宝洁公司 黑素聚集激素拮抗剂
JPWO2005063720A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
EP1902022A1 (en) 2005-07-12 2008-03-26 Glaxo Group Limited Piperazine heteroaryl derivates as gpr38 agonists
TWI376375B (en) * 2005-07-26 2012-11-11 Glaxo Group Ltd Compounds
MX2009000110A (es) * 2006-06-28 2009-01-23 Glaxo Group Ltd Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38.

Also Published As

Publication number Publication date
NO20090266L (no) 2009-03-17
SI2041093T1 (sl) 2010-07-30
DK2041093T3 (da) 2010-08-02
MA30539B1 (fr) 2009-06-01
AU2007263712B2 (en) 2012-08-30
EP2041093B1 (en) 2010-04-21
IL195900A0 (en) 2009-09-01
EP2041093A1 (en) 2009-04-01
ATE465150T1 (de) 2010-05-15
NZ573450A (en) 2011-11-25
TW200817352A (en) 2008-04-16
US8853218B2 (en) 2014-10-07
HRP20100284T1 (hr) 2010-06-30
ES2344484T3 (es) 2010-08-27
DE602007006019D1 (de) 2010-06-02
JP2009541432A (ja) 2009-11-26
JO2645B1 (en) 2012-06-17
KR20090031688A (ko) 2009-03-27
CY1110190T1 (el) 2015-01-14
PL2041093T3 (pl) 2010-09-30
US20080027065A1 (en) 2008-01-31
US7700599B2 (en) 2010-04-20
WO2008000729A1 (en) 2008-01-03
BRPI0713443A2 (pt) 2012-03-06
TWI391386B (zh) 2013-04-01
PT2041093E (pt) 2010-06-28
JP5028484B2 (ja) 2012-09-19
EA200970065A1 (ru) 2009-06-30
MY147677A (en) 2012-12-31
US20090192160A1 (en) 2009-07-30
MX2009000110A (es) 2009-01-23
CA2655540A1 (en) 2008-01-03
EA015820B1 (ru) 2011-12-30
CR10497A (es) 2009-03-20
AR061656A1 (es) 2008-09-10
HK1127608A1 (en) 2009-10-02
AU2007263712A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20091408A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20121614A1 (es) Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20090610A1 (es) Derivados de pirazol sustituidos
PE20090717A1 (es) Derivados de quinolina como inhibidores de la pi3 quinasa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed